MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./290/0.1/21.03.25 Share Price

Warrant

DE000MG0Y1M1

Real-time Bid/Ask 15:26:02 21/05/2024 BST
0.37 EUR / 0.41 EUR +5.41% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./290/0.1/21.03.25
Current month-17.78%
1 month-26.00%
Date Price Change
21/05/24 0.36 -2.70%
20/05/24 0.37 0.00%
17/05/24 0.37 -5.13%
16/05/24 0.39 -7.14%
15/05/24 0.42 +7.69%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 09:14 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG0Y1M
ISINDE000MG0Y1M1
Date issued 27/03/2024
Strike 290 $
Maturity 21/03/2025 (304 Days)
Parity 10 : 1
Emission price 0.6
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.86
Lowest since issue 0.36
Spread 0.04
Spread %10.26%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus